Carl Zeiss Meditec falls after GS cuts to 'sell' on valuation concerns

By Reuters News

** Carl Zeiss Meditec's AFXG.DE shares fall around 4% after Goldman Sachs cut its rating on the medical technology company to "sell" from "neutral", citing a disconnect between valuation and growth prospects

** GS says the stock has rerated despite a deteriorating outlook and meaningful earnings estimate cuts

** It believes the rerating was partly driven by Carl Zeiss Group's June announcement to invest up to €200 million to increase its stake in the company

** As that buying support fades, GS expects the gap between valuation and underlying fundamentals to close

** Cuts its PT on the stock to €23 from €27


($1 = 0.8941 euros)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.